Embryonic stem cells have yet to show a single successful medical use—a fact that has done little to slow down the onslaught of new research projects in the field. Focus has shifted from ethics and mechanics to the bottom line—money and fame. Many private investors are expecting huge returns as states race to build stem-cell research centers with private money—thus, bypassing federal restrictions. The February 4, 2005 issue of Science contained three separate articles that discussed the current progress of embryonic stem-cell research in the United States and abroad.
California got the ball rolling with its $3 billion initiative, designated as “Proposition 71.” Not to be left behind, other states now are clamoring to secure their own piece of the financial pie. For instance, Wisconsin, the state in which the first human embryonic stem cells were derived in 1998, has proposed an investment of $750 million for stem-cell and other biomedical research over the next few years. And New Jersey Governor Richard Codey has proposed using $150 million from unspent bond income to develop the New Jersey Institute for Stem-Cell Research. These states are far from being alone. The signal that many states are sending is: “We want some of this!”
Part of the drive behind this heightened push for embryonic stem-cell research is coming from overseas. American scientists are worried that developing countries such as Singapore, Japan, South Korea, China, and Taiwan are inching ahead with research that is unhindered by governmental and/or societal restrictions.
On February 8, 2005, Ian Wilmut—the man who cloned the sheep, Dolly—was given a license by British regulators to clone human embryos for research. His intent is to produce cloned embryos and harvest the stem cells from those embryos for further study. Then “the remaining cells [from the embryo—BH] will be destroyed.” Wilmut’s is the second license issued that will allow human cloning in the United Kingdom.
With the current seemingly insatiable drive in this field, it hardly seems likely that scientists will pause to consider the ethics of what they are doing. Over twenty-five years ago, we wondered how many lives would be destroyed as a result of the then-new abortion legislation. A new door has now been opened with embryonic research. And yet, embryonic stem cells have yet to show a single successful medical use.
Copyright © 2005 Apologetics Press, Inc. All rights reserved.
This document may be copied, on the condition that it will not be republished in print unless otherwise stated below, and will not be used for any commercial purpose, as long as the following stipulations are observed: (1) Apologetics Press must be designated as the original publisher; (2) the specific Apologetics Press Web site URL must be noted; (3) any references, footnotes, or endnotes that accompany the article must be included with any written reproduction of the article; (4) textual alterations of any kind are strictly forbidden; (5) Some illustrations (e.g., photographs, charts, graphics, etc.) are not the intellectual property of Apologetics Press and as such cannot be reproduced from our site without consent from the person or organization that maintains those intellectual rights; (6) serialization of written material (e.g., running an article in several parts) is permitted, as long as the whole of the material is made available, without editing, in a reasonable length of time; (7) articles, in whole or in part, may not be offered for sale or included in items offered for sale; and (8) articles may be reproduced in electronic form for posting on Web sites pending they are not edited or altered from their original written content and that credit is given to Apologetics Press, including the web location from which the articles were taken. Further, documents may not be copied without source statements (title, author, journal title), and the address of the publisher and owner of rights, as listed below.
For catalog, samples, or further information, contact:
230 Landmark Drive
Montgomery, Alabama 36117
Phone (334) 272-8558